Kolexia
Mabro May Médecine interne
Mabro May
Médecine interne
Hôpital Foch
Suresnes, France
80 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du côlon Adénocarcinome Métastase tumorale Tumeurs du rectum COVID-19 Tumeurs du cerveau Tumeurs de l'estomac Tumeurs du pancréas

Collaborateurs

Voir plus
Andre Thierry
Andre Thierry
Hôpital Saint-Antoine, Paris, France
Louvet Christophe
Louvet Christophe
Institut Mutualiste Montsouris, Paris, France
Tournigand Christophe
Tournigand Christophe
Hôpital Henri Mondor, Créteil, France
Mineur Laurent
Mineur Laurent
Centre Hospitalier de Apt, Apt, France

Industries

Voir plus
Servier
7 collaboration(s)
Dernière en 2023
Amgen
3 collaboration(s)
Dernière en 2023
Lilly
2 collaboration(s)
Dernière en 2023
Pierre Fabre
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.
Journal of the National Comprehensive Cancer Network : JNCCN   16 décembre 2023
IDEA: A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   27 septembre 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   07 mars 2023
1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethics.
BMC medical ethics   28 août 2022
The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
2022 ASCO Annual Meeting I   02 juin 2022
Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial.
2022 ASCO Annual Meeting I   02 juin 2022
Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy.
European journal of cancer (Oxford, England : 1990)   28 octobre 2021
PIMABI: An Open-label Phase II Trial of Panitumumab Plus Irinotecan for Patients With Advanced Metastatic Colorectal Cancer Without KRAS Mutation (Wild-type) in Third-line Chemotherapy (FOLFOX/XELOX ± Bevacizumab and Irinotecan Alone or FOLFIRI/CAPIRI ± Bevacizumab)
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   26 août 2021